{"schema_version":"1","generated_at":"2026-11-18T02:59:05.899Z","data_as_of":"2026-11-13","url":"https://www.findmykol.com/kol/deborah-armstrong","json_url":"https://www.findmykol.com/kol/deborah-armstrong/profile.json","record_kind":"full","profile_kind":"clinical","person":{"slug":"deborah-armstrong","name":"Deborah Armstrong","credential":"MD","title":"Professor of Oncology","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Gynecologic","therapeutic_areas":["Gynecologic","Oncology"],"institution":"Johns Hopkins","institution_url":"https://www.findmykol.com/institution/johns-hopkins-university-school-of-medicine","city":"Lutherville","state":"MD","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"},"country":{"name":"United States","code":"US","status":"verified"}},"identifiers":{"npi":"1437113255"},"summary":"Deborah Armstrong is Professor of Oncology at Johns Hopkins. ClinicalTrials.gov lists 7 registered studies with this person as an investigator.","overview":{"text":"Deborah Armstrong, M.D., is Professor of Oncology at Johns Hopkins. It also documents an investigator role on 7 registered clinical trials, industry payments reported by 5 companies, 4 NIH-funded awards (1999–2026).","bullets":["Top research focus: Ovarian / Gynecologic Cancer","7 registered trials on ClinicalTrials.gov","Open Payments reporting from 5 companies"],"generated_at":"2026-11-17"},"focus":{"indications":[{"label":"Ovarian / Gynecologic Cancer","therapeutic_area":"Oncology","trials":5,"topics":0,"strength":15},{"label":"Brenner Tumor","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Carcinoma, Endometrioid","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Carcinoma, Ovarian Epithelial","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Cystadenocarcinoma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Cystadenocarcinoma, Mucinous","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Cystadenocarcinoma, Serous","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Cysts","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Fallopian Tube Neoplasms","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Peritoneal Neoplasms","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3}],"research_topics":["Ovarian / Gynecologic Cancer","Brenner Tumor","Carcinoma, Endometrioid","Carcinoma, Ovarian Epithelial","Cystadenocarcinoma","Cystadenocarcinoma, Mucinous","Cystadenocarcinoma, Serous","Cysts","Fallopian Tube Neoplasms","Peritoneal Neoplasms"],"drugs_studied":{"total":3,"shown":3,"withheld":0,"rows":[{"name":"Lynparza","generic":"Olaparib","trials":0,"payments":4,"publications":0,"mentions":4},{"name":"Enhertu","generic":"Trastuzumab","trials":0,"payments":2,"publications":0,"mentions":2},{"name":"Xgeva","generic":"Denosumab","trials":0,"payments":1,"publications":0,"mentions":1}]},"works_with":{"total":9,"shown":3,"withheld":6,"rows":[{"name":"AstraZeneca UK Limited","trials":0,"payments":13,"mentions":13},{"name":"Gynecologic Oncology Group","trials":3,"payments":0,"mentions":3},{"name":"AstraZeneca Pharmaceuticals LP","trials":0,"payments":2,"mentions":2}]}},"scholarship":{"note":"Research metrics are not shown for this record: either no confident publication match for this name, or more than one clinician shares the matched author record."},"trials":{"count":7,"shown":3,"withheld":4,"matched_by":"identity-adjudicated record","rows":[{"nct":"NCT00516841","title":"A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer","phase":"PHASE2","status":"TERMINATED","role":"Investigator","sponsor":"Facet Biotech","source_url":"https://clinicaltrials.gov/study/NCT00516841","trial_url":"https://www.findmykol.com/trial/NCT00516841"},{"nct":"NCT00086892","title":"Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer","phase":"PHASE2","status":"COMPLETED","role":"Investigator","sponsor":"Gynecologic Oncology Group","source_url":"https://clinicaltrials.gov/study/NCT00086892","trial_url":"https://www.findmykol.com/trial/NCT00086892"},{"nct":"NCT00049088","title":"Bortezomib and Docetaxel in Treating Patients With Advanced Solid Tumors","phase":"PHASE1","status":"TERMINATED","role":"Investigator","sponsor":"National Cancer Institute (NCI)","source_url":"https://clinicaltrials.gov/study/NCT00049088","trial_url":"https://www.findmykol.com/trial/NCT00049088"}],"source":"trials"},"payments":{"company_count":5,"program_years":{"first":2021,"last":2025},"rows_total":10,"shown":3,"withheld":7,"rows":[{"payer":"AstraZeneca Pharmaceuticals LP","program_year":2025,"amount_usd":2200,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1437113255"},{"payer":"Daiichi Sankyo Inc.","program_year":2025,"amount_usd":1400,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1437113255"},{"payer":"AstraZeneca UK Limited","program_year":2025,"amount_usd":500,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1437113255"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1437113255","source":"payments"},"prescribing":{"data_year":2024,"areas_total":2,"areas_shown":2,"areas":[{"area":"Cancer & immunology","share_pct":68,"classes_total":1,"classes":[{"class":"Aromatase Inhibitor","setting":"prescribed","share_pct":68,"drugs":[{"name":"Anastrozole","share_pct":100}],"max_beneficiaries":null}]},{"area":"Nervous system","share_pct":32,"classes_total":1,"classes":[{"class":"Benzodiazepine","setting":"prescribed","share_pct":32,"drugs":[{"name":"Lorazepam","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"office","data_year":2024,"office_pct":77.8,"facility_pct":22.2},"source":"medicare"},"funding":{"award_count":4,"fiscal_years":{"first":1999,"last":2026},"rows_total":23,"shown":3,"withheld":20,"rows":[{"project":"UG1CA233196","title":"NCTN LAPS at Johns Hopkins","fiscal_year":2026,"amount_usd":468768,"organization":"JOHNS HOPKINS UNIVERSITY","source_url":"https://reporter.nih.gov/quickSearch/UG1CA233196"},{"project":"UG1CA233196","title":"Johns Hopkins University NCTN Lead Academic Site Program","fiscal_year":2025,"amount_usd":522793,"organization":"JOHNS HOPKINS UNIVERSITY","source_url":"https://reporter.nih.gov/quickSearch/UG1CA233196"},{"project":"UG1CA233196","title":"Johns Hopkins University NCTN Lead Academic Site Program","fiscal_year":2024,"amount_usd":568290,"organization":"JOHNS HOPKINS UNIVERSITY","source_url":"https://reporter.nih.gov/quickSearch/UG1CA233196"}],"source":"grants"},"publications":{"total":0,"shown":0,"withheld":0,"recent":[],"source":"works"},"presence":{"mentions":{"total":9,"shown":3,"rows":[{"url":"https://www.doximity.com/cv/deborah-armstrong-md-f8089f46","platform":"doximity","status":"provisional"},{"url":"https://www.facebook.com/hopkinskimmel/posts/ovariancancer-is-notoriously-difficult-to-detect-says-dr-deborah-armstrong-a-med/1487566533406259/","platform":"facebook","status":"verified"},{"url":"https://ascopost.com/issues/september-25-2021-supplement-gynecologic-cancers-almanac/epov-deborah-armstrong/","platform":"other","status":"provisional"}]},"verified_means":"confirmed in more than one place; provisional means found and still being confirmed"},"recognition":{"education":{"total":3,"shown":3,"rows":[{"value":"MD","source_url":"https://care.healthline.com/find-care/provider/dr-deborah-armstrong-1437113255","status":"provisional","collected_at":"2026-11-13"},{"value":"Board certified in Internal Medicine (per directory listing)","source_url":"https://care.healthline.com/find-care/provider/dr-deborah-armstrong-1437113255","status":"provisional","collected_at":"2026-11-13"},{"value":"Graduated from George Washington University School of Medicine & Health Sciences (per directory listing)","source_url":"https://care.healthline.com/find-care/provider/dr-deborah-armstrong-1437113255","status":"provisional","collected_at":"2026-11-13"}]},"roles":{"total":9,"shown":3,"rows":[{"value":"Serves on the Medical Oncology, Developmental Therapeutics and Phase I GOG committees, Gynecologic Oncology Group","source_url":"https://profiles.hopkinsmedicine.org/provider/deborah-k-armstrong/2706154","status":"verified","collected_at":"2026-11-13"},{"value":"Representative of the Southwest Oncology Group to the Gynecologic Cancer Steering Committee of the National Cancer Institute","source_url":"https://profiles.hopkinsmedicine.org/provider/deborah-k-armstrong/2706154","status":"verified","collected_at":"2026-11-13"},{"value":"Representative of Johns Hopkins to the National Cooperative Cancer Network, ovarian and breast cancer risk reduction panels","source_url":"https://profiles.hopkinsmedicine.org/provider/deborah-k-armstrong/2706154","status":"verified","collected_at":"2026-11-13"}]},"secondary_affiliations":{"total":2,"shown":2,"rows":[{"value":"Director, Breast and Ovarian Surveillance Service","source_url":"https://ascopost.com/news/march-2021/maintenance-olaparib-yields-strong-and-sustained-benefit-in-ovarian-cancer/","status":"provisional","collected_at":"2026-11-13"},{"value":"Directs the medical gynecologic oncology clinical service","source_url":"https://profiles.hopkinsmedicine.org/provider/deborah-k-armstrong/2706154","status":"verified","collected_at":"2026-11-13"}]},"media":{"total":4,"shown":3,"rows":[{"value":"Named in Johns Hopkins newsroom release on gynecologic cancers webinar series (2020)","source_url":"https://www.hopkinsmedicine.org/news/newsroom/news-releases/2020/09/johns-hopkins-hosts-webinar-series-about-gynecologic-cancers-and-survivorship","status":"provisional","collected_at":"2026-11-13"},{"value":"Expert Point of View, ASCO Post Gynecologic Cancers almanac supplement","source_url":"https://ascopost.com/issues/september-25-2021-supplement-gynecologic-cancers-almanac/epov-deborah-armstrong/","status":"provisional","collected_at":"2026-11-13"},{"value":"Invited discussant on maintenance olaparib study, ASCO Post coverage","source_url":"https://ascopost.com/news/march-2021/maintenance-olaparib-yields-strong-and-sustained-benefit-in-ovarian-cancer/","status":"provisional","collected_at":"2026-11-13"}]},"public_positions":{"total":1,"shown":1,"rows":[{"value":"Co-author, Society of Gynecologic Oncology practice statement on frontline PARPi maintenance therapy in ovarian cancer","source_url":"https://www.sgo.org/news/practice-statement-on-frontline-parpi-maintenance-therapy-in-ovca-published/","status":"verified","collected_at":"2026-11-13"}]}},"similar":[{"name":"Anil Sood","slug":"anil-sood","institution":"The University of Texas MD Anderson Cancer Center","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/anil-sood","json_url":"https://www.findmykol.com/kol/anil-sood/profile.json"},{"name":"Beth Karlan","slug":"beth-karlan","institution":"University of California, Los Angeles","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/beth-karlan","json_url":"https://www.findmykol.com/kol/beth-karlan/profile.json"},{"name":"Robert Bast","slug":"robert-bast","institution":"The University of Texas MD Anderson Cancer Center","specialty":"Hematology","url":"https://www.findmykol.com/kol/robert-bast","json_url":"https://www.findmykol.com/kol/robert-bast/profile.json"},{"name":"Baha Sibai","slug":"baha-sibai","institution":"McGovern Medical School at UTHealth Houston","specialty":"Maternal & Fetal Medicine","url":"https://www.findmykol.com/kol/baha-sibai","json_url":"https://www.findmykol.com/kol/baha-sibai/profile.json"}],"coverage":{"note":"An identity-adjudicated profile: every section above was checked. Where a section states a count of zero, the public record was searched and nothing was found."},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"trials":4,"payments":7,"funding":20}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies","collected_at":"2026-11-13"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 to 2025","collected_at":"2026-11-13"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year","collected_at":"2026-11-13"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"}},"methodology_url":"https://www.findmykol.com/about#methodology"}